Abstract
Immune checkpoint blockade (ICB) has been proven to be an effective strategy for enhancing the effector activity of anti-tumor T cells, and checkpoint blockers targeting CTLA-4, PD-1, and PD-L1 have displayed strong and durable clinical responses in certain cancer patients. The new hope brought by ICB therapy has led to the boost in therapeutic development of ICBs in recent years. Nonetheless, the therapeutic efficacy of ICBs varies substantially among cancer types and patients, and only a proportion of cancer patients could benefit from ICBs. The emerging targets and molecules for enhancing anticancer immunity may bring additional therapeutic opportunities for cancer patients. The current challenges in the ICB therapy have been discussed, aimed to provide further strategies for maximizing the efficacy of ICB therapy.
Keywords
- Immune checkpoint blocker
- CTLA-4
- PD-1
- PD-L1
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alexander M, Mellor JD, McArthur G, Kee D (2014) Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med J Aust 201(1):49–53
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421
Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44(5):989–1004
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A et al (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17(3):299–308
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350
Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J et al (2018) Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol Res 6(2):189–200
Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S et al (2019) A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer 145(3):639–648
Ascierto PA, McArthur GA (2017) Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? J Transl Med 15(1):173
Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA et al (2017) Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res 23(19):5671–5678 An Official Journal of the American Association for Cancer Research
Barone A, Hazarika M, Theoret MR, Mishra-Kalyani P, Chen H, He K et al (2017) FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin Cancer Res 23(19):5661–5665 An Official Journal of the American Association for Cancer Research
Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G et al (2017) Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35(1):40–47 Official Journal of the American Society of Clinical Oncology
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026
Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM (2005) Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4 + T cells. Blood 105(4):1574–1581
Borrie AE, Maleki Vareki S (2018) T lymphocyte-based cancer immunotherapeutics. Int Rev Cell Mol Biol 341:201–276
Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H et al (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9(47):28561–28571
Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A et al (2017) Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 18(12):1600–1609
Burgess EF, Livasy C, Hartman A, Robinson MM, Symanowski J, Naso C, et al (2019) Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol 37(5):299 e19–e25
Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M (2019) Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 12(5):453–470
Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E et al (2014) Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Investig Dermatol 134(7):1893–1902
Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229–1241
Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C et al (2015) TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Investig 125(5):2046–2058
Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945–954
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma. J Clin Oncol 35(19):2125–2132 Official Journal of the American Society of Clinical Oncology
Chen C, Zhang F, Zhou N, Gu YM, Zhang YT, He YD et al (2019a) Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology 8(5):e1581547
Chen Q, Wang J, Chen W, Zhang Q, Wei T, Zhou Y et al (2019b) B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. Cancer Sci 110(2):530–539
Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R et al (2017) Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 114(29):E5900–E5909
Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L et al (2014) Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exper Clin Cancer Res CR 33:30
Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L et al (2014) PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25(11):2178–2184 Official Journal of the European Society for Medical Oncology
Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C (2018) Immunotherapy in lung cancer: a new age in cancer treatment. Adv Exper Med Biol 995:65–95
Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT et al (2017) A retrospective analysis of the efficacy of pembrolizumab in melanoma patients with brain metastasis. J Immunother 40(3):108–113
Dang TO, Ogunniyi A, Barbee MS, Drilon A (2016) Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther 16(1):13–20
D’Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P et al (2017) Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab. Clin Cancer Res 23(12):2972–2980 An Official Journal of the American Association for Cancer Research
D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19(3):416–426
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A et al (2016) Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 375(2):143–153
Deeks ED (2016) Pembrolizumab: a review in advanced melanoma. Drugs 76(3):375–386
Dempke WCM, Fenchel K, Uciechowski P, Dale SP (2017) Second- and third-generation drugs for immuno-oncology treatment-the more the better? Eur J Cancer 74:55–72
Deng WW, Mao L, Yu GT, Bu LL, Ma SR, Liu B et al (2016) LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Oncoimmunology 5(11):e1239005
Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T et al (2018) Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol 200(8):3000–3007
Dougall WC, Kurtulus S, Smyth MJ, Anderson AC (2017) TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev 276(1):112–120
Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA et al (2014) Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS ONE 9(11):e109080
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378(19):1789–1801
Engelhardt JJ, Sullivan TJ, Allison JP (2006) CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol 177(2):1052–1061
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837–1846
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867
Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24(12):1845–1851
Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B et al (2014) PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res 74(4):1045–1055
Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K, et al (2019) TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. Clin Cancer Res. An Official journal of the American Association for Cancer Research
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y et al (2018) Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 24(9):1441–1448
Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al (2016) Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy. Cell 167(2):397–404 e9
Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T (2017) Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review. Crit Rev Oncology/Hematology 120:86–92
Gato-Canas M, Zuazo M, Arasanz H, Ibanez-Vea M, Lorenzo L, Fernandez-Hinojal G et al (2017) PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep 20(8):1818–1829
Ghorpade DS, Kaveri SV, Bayry J, Balaji KN (2011) Cooperative regulation of NOTCH1 protein-phosphatidylinositol 3-kinase (PI3K) signaling by NOD1, NOD2, and TLR2 receptors renders enhanced refractoriness to transforming growth factor-beta (TGF-beta)- or cytotoxic T-lymphocyte antigen 4 (CTLA-4)-mediated impairment of human dendritic cell maturation. J Biol Chem 286(36):31347–31360
Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al (2019) Distinct immune cell populations define Response to Anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 35(2):238–55 e6
Goldberg MV, Drake CG (2011) LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 344:269–278
Graziani G, Tentori L, Navarra P (2012) Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 65(1):9–22
Guillerey C, Harjunpaa H, Carrie N, Kassem S, Teo T, Miles K et al (2018) TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood 132(16):1689–1694
Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M et al (2015) Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42(2):344–355
Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Poschinger T, et al (2019) Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma. Hepatology
Hamada T, Soong TR, Masugi Y, Kosumi K, Nowak JA, da Silva A et al (2018) TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology 7(7):e1442999
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T et al (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33(34):4015–4022 Official Journal of the American Society of Clinical Oncology
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582–588 Official Journal of the European Society for Medical Oncology
Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD et al (2017) Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 35(34):3851–3858 Official Journal of the American Society of Clinical Oncology
He W, Zhang H, Han F, Chen X, Lin R, Wang W et al (2017) CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res 77(22):6375–6388
He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR (2018) TIM-3, a promising target for cancer immunotherapy. OncoTargets Ther 11:7005–7009
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093–2104
Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A et al (2019) Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 35(2):329
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550
Hermel DJ, Sigal D, The emerging role of checkpoint inhibition in microsatellite stable colorectal cancer. J Personal Med 9(1) (2019)
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723
Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11):1558–1568
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35(35):3924–3933 Official Journal of the American Society of Clinical Oncology
Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229
Ishihara J, Ishihara A, Sasaki K, Lee SS, Williford JM, Yasui M, et al (2019) Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med 11(487)
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P et al (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36(28):2836–2844 Official Journal of the American Society of Clinical Oncology
Jiang DM, Fyles A, Nguyen LT, Neel BG, Sacher A, Rottapel R et al (2019) Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. Oncotarget 10(31):2947–2958
Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A et al (2019) VISTA is an acidic pH-selective ligand for PSGL-1. Nature 574(7779):565–570
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471
Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R (2017) FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. Oncologist 22(5):585–591
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17(10):1374–1385
Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13(5):273–290
Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J et al (2019) The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur Urol 75(6):961–964
Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP et al (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30(20):2509–2515 Official Journal of the American Society of Clinical Oncology
Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S et al (2015) The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res 3(9):999–1007
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG et al (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501
Kudo M (2019) Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. World J Gastroenterol 25(7):789–807
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49
Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW et al (2015) TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Investig 125(11):4053–4062
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700–712
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ (2018) Pd-L1. J Clin Pathol 71(3):189–194
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497–1508
Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(13):1270–1271
Larkins E, Blumenthal GM, Yuan W, He K, Sridhara R, Subramaniam S et al (2017) FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist 22(7):873–878
Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P et al (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res 74(7):1933–1944
Lebbe C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P et al (2019) Evaluation of two dosing regimens for Nivolumab in combination with Ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol 37(11):867–875 Official Journal of the American Society of Clinical Oncology
Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ et al (2019) Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 7(4):347–357
Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S et al (2014) VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74(7):1924–1932
Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1(9):793–801
Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17(22):6958–6962 An Official Journal of the American Association for Cancer Research
Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD et al (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A 112(21):6682–6687
Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J et al (2018) Combination Immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther J Am Soc Gene Ther 26(1):45–55
Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, et al (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer—clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. Official Journal of the European Society for Medical Oncology
Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y et al (2018) The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer 9(5–6):176–189
Lu X, Yang L, Yao D, Wu X, Li J, Liu X et al (2017) Tumor antigen-specific CD8(+) T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer. Cell Immunol 313:43–51
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046–2054 Official Journal of the American Society of Clinical Oncology
Maio M, Scherpereel A, Calabro L, Aerts J, Cedres Perez S, Bearz A et al (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18(9):1261–1273
Manser AR, Uhrberg M (2016) Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance. Cancer Immunol Immunother CII 65(4):417–426
Marcus L, Lemery SJ, Keegan P, Pazdur R (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25(13):3753–3758 An Official Journal of the American Association for Cancer Research
Marginean EC, Melosky B (2018) Is there a role for programmed death ligand-1 testing and immunotherapy in colorectal cancer with microsatellite instability? Part I-colorectal cancer: microsatellite instability, testing, and clinical implications. Arch Pathol Lab Med 142(1):17–25
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359(6371):104–108
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T et al (2010) Tumor-infiltrating NY-ESO-1-specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107(17):7875–7880
McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ et al (2016) Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology 5(10):e1226720
Middha S, Yaeger R, Shia J, Stadler ZK, King S, Guercio S, et al (2019) Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high. JCO Precis Oncol 3
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379(4):341–351
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830
Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K et al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446–453
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813
Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S et al (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17(6):717–726
Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R et al (2017) Immunoregulatory functions of VISTA. Immunol Rev 276(1):66–79
Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T et al (2011) PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exper Med 208(2):395–407
O’Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B et al (2007) A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13(3):958–964 An Official Journal of the American Association for Cancer Research
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–1191
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779 Official Journal of the American Society of Clinical Oncology
Pahl J, Cerwenka A (2017) Tricking the balance: NK cells in anti-cancer immunity. Immunobiology 222(1):11–20
Panjwani PK, Charu V, DeLisser M, Molina-Kirsch H, Natkunam Y, Zhao S (2018) Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol 71:91–99
Park R, Williamson S, Kasi A, Saeed A (2018) Immune therapeutics in the treatment of advanced gastric and esophageal cancer. Anticancer Res 38(10):5569–5580
Park R, Winnicki M, Liu E, Chu WM (2019) Immune checkpoints and cancer in the immunogenomics era. Brief Funct Genomics 18(2):133–139
Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV et al (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25(21):9543–9553
Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R et al (2018) Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19(1):51–64
Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exper Med 206(8):1717–1725
Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, et al (2019) Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 27(8):2411–2425 e9
Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B et al (2016) Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44(6):1255–1269
Polk A, Svane IM, Andersson M, Nielsen D (2018) Checkpoint inhibitors in breast cancer—current status. Cancer Treat Rev 63:122–134
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558–562
Powles T, O’Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ et al (2017) Efficacy and Safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 3(9):e172411
Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O’Brien ME (2010) Treatment options for small cell lung cancer—do we have more choice? Br J Cancer 102(4):629–638
Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM et al (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029):600–603
Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL et al (2010) Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 16(5):1662–1672 An Official Journal of the American Association for Cancer Research
Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al (2013) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24(1):75–83 Official Journal of the European Society for Medical Oncology
Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W et al (2016) Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34(31):3740–3748 Official Journal of the American Society of Clinical Oncology
Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G et al (2017) Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35
Ribas A (2010) Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 37(5):450–454
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–622 Official Journal of the American Society of Clinical Oncology
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128
Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al (2015b) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3):257–265
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330
Roberto A, Di Vito C, Zaghi E, Mazza EMC, Capucetti A, Calvi M et al (2018) The early expansion of anergic NKG2A(pos)/CD56(dim)/CD16(neg) natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. Haematologica 103(8):1390–1402
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–97
Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67
Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US et al (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33(8):828–833
Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM et al (2018) Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther 17(3):671–676
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51(2):202–206
Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, et al (2019) DNAM-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers 11(6)
Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59(1):81–88
Sansom DM (2000) CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 101(2):169–177
Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853–1862
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894 Official Journal of the American Society of Clinical Oncology
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O et al (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20(2):239–253
Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ et al (2003) Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 106(6):905–912
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312–322
Sim F, Leidner R, Bell RB (2019) Immunotherapy for head and neck cancer. Oral Maxillofac Surg Clin N Am 31(1):85–100
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ et al (2013) Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24(7):1813–1821 Official Journal of the European Society for Medical Oncology
Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P et al (2019) Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. J Immunother Cancer 7(1):40
Solomon BL, Garrido-Laguna I (2018) TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother CII. 67(11):1659–1667
Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571
Vigano S, Alatzoglou D, Irving M, Menetrier-Caux C, Caux C, Romero P et al (2019) Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front Immunol 10:925
Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exper Med 208(3):577–592
Wang Z, Zhu J, Gu H, Yuan Y, Zhang B, Zhu D et al (2015) The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer. Immunol Investig 44(6):578–589
Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G et al (2018) CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol 190:64–73
Wang C, Sandhu J, Fakih M (2019a) Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. J Gastrointest Oncol 10(1):161–165
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al (2019) Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176(1–2):334–347 e12
Wang J, Wu G, Manick B, Hernandez V, Renelt M, Erickson C et al (2019c) VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology 156(1):74–85
Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD et al (2013) Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31(34):4311–4318 Official Journal of the American Society of Clinical Oncology
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72(4):917–927
Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V et al (2019) Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology 69(5):2048–2060
Xu B, Yuan L, Gao Q, Yuan P, Zhao P, Yuan H et al (2015) Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget 6(24):20592–20603
Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J et al (2017) PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 23(12):3158–3167 An Official Journal of the American Association for Cancer Research
Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS (2018) Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. Thorac Cancer 9(6):736–744
Yu GT, Mao L, Wu L, Deng WW, Bu LL, Liu JF et al (2018) Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma. Cell Mol Life Sci CMLS 75(22):4223–4234
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N et al (2019) Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥ 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer 107:142–152
Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J et al (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111(1):251–259
Zhang T, Wang J, Zhou X, Liang R, Bai Q, Yang L et al (2014) Increased expression of TIGIT on CD4 + T cells ameliorates immune-mediated bone marrow failure of aplastic anemia. J Cell Biochem 115(11):1918–1927
Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W et al (2018) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19(7):723–732
Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, et al (2017) Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology 153(4):1107–1119 e10
Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G et al (2015) An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun 6:6072
Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P et al (2015a) Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med 13:351
Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J et al (2015b) Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS ONE 10(3):e0118564
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Wang, J., Yang, T., Xu, J. (2020). Therapeutic Development of Immune Checkpoint Inhibitors. In: Xu, J. (eds) Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, vol 1248. Springer, Singapore. https://doi.org/10.1007/978-981-15-3266-5_23
Download citation
DOI: https://doi.org/10.1007/978-981-15-3266-5_23
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-3265-8
Online ISBN: 978-981-15-3266-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)